Silver Book Fact

In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.

Katz N, Borenstein D, Birbara C, Bramson C, et al. Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain. Pain. 2011; 152(10): 2248-58. http://www.painjournalonline.com/article/S0304-3959%2811%2900316-2/abstract

Reference

Title
Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain
Publication
Pain
Publication Date
2011
Authors
Katz N, Borenstein D, Birbara C, Bramson C, et al.
Volume & Issue
Volume 152, Issue 10
Pages
2248-58
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Understanding the role of genetics in pain mechanisms is increasing and the potential now exists to conduct genome-wide screens in model organisms to look for pain-associated genes.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • The Mayo Clinic Pain Rehabilitation Center helps people with persistent pain return to an active lifestyle and has found that among patients who finish the program, nearly 84% report greater…  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.  
  • A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.